Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of October 2023. The document serves as a notice of an Extraordinary General Meeting of Shareholders scheduled for November 16, 2023, at the company's offices in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notice and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary corporate action proposed is an increase in the Company's authorized share capital.
Guidance, Outlook, and Management Commentary
- Meeting Purpose: The sole agenda item is to approve the increase of the Company's authorized share capital.
- Management Recommendation: The Board of Directors recommends that shareholders vote FOR the proposal.
- Record Date: Holders of record of Ordinary Shares and ADSs as of the close of business on October 16, 2023, are entitled to vote.
- Shareholder Rights: Shareholders may submit a written "Position Statement" by November 7, 2023, to express their views on the agenda item.
Key Facts for Investor Verification
- Verify the specific details of the proposed increase in authorized share capital in the proxy materials provided separately.
- Confirm the record date of October 16, 2023, to determine voting eligibility.
- Note the meeting date of November 16, 2023, and the requirement for proxies to be received four hours prior to the meeting.
- Check the company website (http://www.redhillbio.com) for the full text of the proposed resolutions and proxy card.